- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
In-depth analysis of the grey areas, emerging risks, and practical lessons that matter to compliance leads, signatories, and medical affairs teams.
Anzal Qurbain
12 Feb 2026 · 7 min read
I have seen the supposedly innocent disease-awareness flyers! If you think ‘non-promotional’ means ‘risk-free,’ you’re in for a surprise – and so was the team that found themselves knee-deep in…
Let me tell you about a moment in 2024 that jolted me: an utterly compliant disease-awareness campaign unravelled…
Tired teams, last-minute campaigns, and a swirl of regulatory updates — the Christmas run-up in pharma is always…
I still remember the LinkedIn post that landed in my inbox at 7:30 a.m. — a well-meaning disease-awareness…
In this short piece I’ll step into the signatory seat and explain what risk assessment actually looks like…
I review 100’s of clinician videos and often i think: technically great, strategically risky. In CASE/0360/11/24 (Complainant v…
I read the PMCPA Social Media Guidance 2026 with a notebook and a headache. As an ABPI Final…
Ask one of 13 specialist ABPI advisors — instant answers, 24/7. No waiting, no gatekeeping.
12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.
One real case. One key lesson. Every week — free.